Teva Pharmaceutical Industries Ltd – Lobbying Governance & Transparency

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Lobbying Governance

Overall Assessment	Analysis	Score
Limited	Teva provides limited insight into how it governs lobbying and other external engagement in relation to its climate objectives. The company states that it "has a dedicated ESG governance structure and ESG team which developed an ESG strategy in 2020 which includes Climate Action and Resiliency as a material topic," and notes that it "abides by its Position on Government Affairs," yet neither disclosure explains who specifically oversees lobbying activities, how they are reviewed, or what procedures are used to ensure alignment. Teva confirms that it "does your organization have a public commitment or position statement to conduct your engagement activities in line with the goals of the Paris Agreement? […] Yes," indicating a high-level pledge to align engagement with Paris goals, and points to memberships such as the "European Federation of Pharmaceutical Industries and Associations (EFPIA)" whose white paper on climate change is broadly supportive of EU climate policy. However, aside from listing these associations and highlighting its own SBTi commitment, the evidence offers no description of a formal monitoring process, no examples of assessing or challenging trade-association positions, and no identification of a board committee or executive who approves or audits lobbying alignment. Consequently, while Teva discloses a commitment to Paris-aligned engagement, the company does not disclose a structured governance framework, named oversight body, or systematic review mechanism for either its direct or indirect lobbying activities. View Sources	D

Overall Assessment

Analysis

Score

Limited

Teva provides limited insight into how it governs lobbying and other external engagement in relation to its climate objectives. The company states that it "has a dedicated ESG governance structure and ESG team which developed an ESG strategy in 2020 which includes Climate Action and Resiliency as a material topic," and notes that it "abides by its Position on Government Affairs," yet neither disclosure explains who specifically oversees lobbying activities, how they are reviewed, or what procedures are used to ensure alignment. Teva confirms that it "does your organization have a public commitment or position statement to conduct your engagement activities in line with the goals of the Paris Agreement? […] Yes," indicating a high-level pledge to align engagement with Paris goals, and points to memberships such as the "European Federation of Pharmaceutical Industries and Associations (EFPIA)" whose white paper on climate change is broadly supportive of EU climate policy. However, aside from listing these associations and highlighting its own SBTi commitment, the evidence offers no description of a formal monitoring process, no examples of assessing or challenging trade-association positions, and no identification of a board committee or executive who approves or audits lobbying alignment. Consequently, while Teva discloses a commitment to Paris-aligned engagement, the company does not disclose a structured governance framework, named oversight body, or systematic review mechanism for either its direct or indirect lobbying activities.

View Sources

Lobbying Transparency

Overall Assessment	Analysis	Score
Moderate	Teva Pharmaceutical Industries provides a fair level of transparency on its climate-policy lobbying. It identifies a concrete engagement with Israel’s voluntary “Zero Hour” mechanism, explaining that this initiative is designed to guide companies in setting Paris-aligned greenhouse-gas reduction targets. The company explains how it sought to influence that policy—by supplying input during the drafting phase at the request of the Israeli Environmental Protection Ministry, by presenting its science-based target-setting experience at launch events, and by participating in the Israeli delegation to UNFCCC COP27—while naming the Ministry as the principal policymaking target. Teva also sets out the outcomes it is pursuing: it supports implementation of Zero Hour to help local businesses adopt science-based targets, yet it wants the scheme modified so that its requirements do not conflict with the company’s existing SBTi-approved goals and so that the policy’s geographic focus extends beyond Israeli operations. Together, these disclosures outline clear mechanisms and desired policy changes, even though only one specific policy is covered, resulting in a moderate overall level of lobbying transparency.	C